Horizon Pharma (HZNP) Announces ACTIMMUNE Phase 3 in FA Missed Primary Endpoint
Tweet Send to a Friend
Horizon Pharma plc (Nasdaq: HZNP) announced that the Phase 3 trial, STEADFAST (Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE